Questions From the Repair Record

What does BPC-157 do in the body?

In animal models, BPC-157 is described as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis — the growth of new blood vessels. The best-characterised pathway is up-regulation and internalisation of the VEGFR2 receptor with downstream VEGFR2-Akt-eNOS signalling; work in chick chorioallantoic membrane, rat hindlimb ischaemia and human vascular endothelial cells reported increased vessel density and accelerated blood-flow recovery, with the effect blocked when endocytosis was inhibited ^[4]. Additional described routes include FAK-paxillin signalling associated with cell migration, sensitisation of the growth-hormone receptor in tendon fibroblasts, and modulation of the nitric-oxide system. A 2016 review also positions it as a brain-gut-axis mediator that modulates serotonergic and dopaminergic systems ^[7]. Every one of those descriptions comes from animal or cell-culture work, not from human studies.

Is BPC-157 a growth hormone?

No. BPC-157 is a 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Human growth hormone is a 191-amino-acid protein released by the pituitary gland, and the two are unrelated in sequence, size and origin.

The confusion has a real root, though. One of the mechanisms attributed to BPC-157 is sensitisation of the growth-hormone receptor in tendon fibroblasts — that is, making cells more responsive to growth hormone the body already produces, rather than supplying any hormone itself. That is a different claim from being a growth hormone, and it is a cell-culture observation. BPC-157 is classed in this corpus as a pentadecapeptide cytoprotective and regenerative research peptide, and it is not an approved drug of any kind.

Does BPC-157 work immediately?

The measured record cannot answer this, and the gap is worth stating plainly because it is the question this site is organised around.

No study in this corpus reports an onset time for BPC-157 in any species. The animal repair studies score an endpoint — tendon integrity, ulcer area, vessel density — at a moment chosen by the investigators, without establishing when the effect began ^[5][6]. What is measured is the opposite end of the problem: a 2022 pharmacokinetic study in rats and beagle dogs found an elimination half-life under 30 minutes, with rapid breakdown into small peptide fragments ^[3]. So the molecule itself is gone quickly, while the outcomes credited to it take days to score.

People in research-use communities frequently describe changes within the first one to three weeks. That is anecdotal, not clinical evidence, and no controlled study has tested it.

Does BPC-157 damage the liver?

No published study in this corpus reports liver damage from BPC-157, but the evidence base is far too small to call it liver-safe.

The only direct human measurement is a first-in-human intravenous safety pilot in which BPC-157 at up to 20 mg was given to two healthy adults — a 58-year-old man and a 68-year-old woman — and was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. Hepatic markers were among the things checked, and they did not move. The sample was two people.

Against that, a 2025 narrative review concluded that human data are extremely limited, that rigorous large-scale trials are lacking, and that the compound should be treated as investigational ^[2], and a 2025 systematic review across 36 studies found no clinical safety data at all ^[13]. An unregulated product also carries the separate risk that what is in the vial is not what the label says.

What is TB-500?

TB-500 is a synthetic, N-terminally acetylated seven-amino-acid peptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, usually written Ac-LKKTETQ. It corresponds to residues 17 to 23 of thymosin beta-4, a naturally occurring 43-amino-acid protein, and that stretch is the conserved actin-binding motif of the beta-thymosins.

The distinction between the fragment and the whole protein is the most important thing to carry away. In commerce and in the anti-doping literature, 'TB-500' means the roughly 889-dalton heptapeptide. Most published efficacy research uses full-length thymosin beta-4 at roughly 4,963 daltons ^[10]. Whether the isolated fragment reproduces the parent protein's effects has not been established in any controlled human trial. TB-500 has no approved therapeutic indication and is prohibited in sport.

What does TB-500 stand for and what does TB stand for in TB-500?

TB stands for thymosin beta — specifically thymosin beta-4, the parent protein that TB-500 is a fragment of. Thymosin beta-4 is encoded by the gene TMSB4X and is the major intracellular G-actin-sequestering peptide in mammalian cells.

The '500' is a product designation rather than a scientific one; it does not encode a molecular weight, a sequence position or a dose. The peptide also appears in the literature and in commerce as Ac-LKKTETQ, N-acetyl-LKKTETQ, the thymosin beta-4 17-23 fragment, the thymosin β4 actin-binding fragment, and — in veterinary contexts — as TB-500 or TB1000.

What is TB-500 used for in research?

In published research, the work is overwhelmingly done on the parent protein rather than the fragment, and it spans tissue repair, wound healing and neurological recovery.

A 2012 review consolidates the picture: thymosin beta-4 binds actin and promotes cell mobilisation, migration and stem-cell activity, decreases myofibroblast number and so reduces scar formation, is released by platelets and macrophages after injury where it limits apoptosis, inflammation and microbial growth, and promotes angiogenesis — the basis for clinical trials in dermal wounds, corneal injury and cardiac and central-nervous-system repair ^[10]. In a rat embolic-stroke model, intraperitoneal thymosin beta-4 begun 24 hours after the stroke improved neurological function significantly from day 14 through day 56 at 2 and 12 mg/kg ^[9]. A 2 ångström crystal structure established the one-to-one actin-sequestration mechanism behind all of it ^[12].

For the heptapeptide sold as TB-500 specifically, there are no completed controlled human trials for any indication.

Does TB-500 work for muscle tears and recovery from exercise?

No controlled human study has tested that, and one animal result argues directly for caution.

A 2026 Sports Medicine narrative review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, which lists TB-500 and thymosin beta-4 among the unapproved compounds, concluded that many show favourable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, that there is potential for serious harm, and that these compounds operate largely outside regulatory oversight ^[8].

The cautionary animal finding is more specific. In dystrophin-deficient mice, long-term thymosin beta-4 increased the number of regenerating muscle fibres but did not improve muscle strength, cardiac function or fibrosis. More regeneration on the histology slide did not translate into better function — which is the single most useful corrective to the assumption that a felt improvement means structural repair. TB-500 is also prohibited in sport, with validated detection methods in use.

What is the Wolverine peptide blend?

'Wolverine' is a name used in the research-use community for a co-formulated pairing of two separate peptides: BPC-157 and TB-500. It is not a single chemical entity, and it has no molecular weight, CAS number or structure of its own — only those of its two constituents.

It also circulates as the BPC-157/TB-500 blend, the BPC-157 + TB-500 stack, the Wolverine peptide stack and BPC157 TB500. Neither component is approved by the FDA for human use, the blend has no approved therapeutic indication, and both constituents are prohibited by the World Anti-Doping Agency. It is sold by research suppliers for laboratory research use only.

What is BPC-157 and TB-500?

They are two structurally unrelated synthetic peptides that happen to be studied for overlapping purposes.

BPC-157 is a 15-amino-acid pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, around 1,419.5 daltons, derived from a partial sequence of a Body Protection Compound found in human gastric juice. Its repair effects in animals are linked chiefly to angiogenesis through the VEGFR2 pathway ^[4].

TB-500 is a synthetic acetylated heptapeptide, Ac-LKKTETQ, around 889.0 daltons, corresponding to the actin-binding region of the 43-residue protein thymosin beta-4. Its mechanism is one-to-one sequestration of monomeric actin, established by crystallography at 2 ångström resolution ^[12].

They share no sequence and act through different pathways. Both are unapproved research compounds and both are prohibited in sport.

What is the BPC-157 and TB-500 blend used for in research?

It is not used in research. That is the accurate answer, and it is easy to miss because the blend is heavily discussed elsewhere.

A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical and one human, a 12-patient retrospective report on intra-articular treatment for knee pain — found no clinical safety data, graded the evidence at levels IV to V, and made no mention of TB-500 or of any combination or blend ^[13]. A review that surveys the field and never encounters the combination is direct evidence that controlled combination research does not exist.

The individual components have their own literatures, summarised on the BPC-157 and TB-500 pages. The pairing has no study, no defined ratio, no measured onset and no measured duration.

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The stated rationale is complementary mechanisms. BPC-157 is credited with a local cytoprotective and pro-angiogenic signal through VEGFR2-Akt-eNOS up-regulation and nitric-oxide modulation ^[4], while TB-500, through the thymosin beta-4 actin-binding motif, is credited with regulating the cytoskeletal dynamics behind cell migration, re-epithelialisation and progenitor mobilisation ^[10]. Two largely non-overlapping pathways, so the argument runs, should reinforce each other.

That is a theoretical extrapolation from each peptide's independently characterised mechanism, not a finding. No controlled head-to-head or combination study has defined a synergistic dose, ratio or endpoint for the two given together ^[13]. Community loading-then-maintenance schedules and fixed 10 mg plus 10 mg vial ratios have no basis in any controlled human trial, and the one formal dose-response experiment in this corpus found that the highest dose tested produced no benefit at all ^[9].